MedTrace Logo

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2025-12-16

No results posted yet for this study

Summary

This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).

Conditions

Interventions

DRUG

MYTX-011

MYTX-011 will be administered as an intravenous infusion every 21 days.

Sponsors & Collaborators

  • Mythic Therapeutics

    lead INDUSTRY

Principal Investigators

  • Ting Wu, MD MSc · Mythic Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-23
Primary Completion
2025-10-31
Completion
2025-11-07
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652868 on ClinicalTrials.gov